Results 281 to 290 of about 87,373 (338)

Complement C3a promotes the formation of osteoclasts by inhibiting Sirt1 to activate the PI3K/PDK1/SGK3 pathway in patients with multiple myeloma. [PDF]

J Transl Med
Jiang F, Zhang Y, Peng F, Liu H, Ding K, Cao P, Liu X, Li L, Liu Z, Fu R.   +9 more
europepmc   +1 more source

Progress of immune senescence in multiple myeloma treatment resistance. [PDF]

Discov Oncol
Jia Y, Yan L, Fan C, Sun H, Zhou X, Shi Z.   +5 more
europepmc   +1 more source

Leveraging a disulfidptosis-based signature to characterize heterogeneity and optimize treatment in multiple myeloma. [PDF]

Front Immunol
Zhang B, Zheng D, Zhu S, Zhang X, Wang Q, Lin Z, Zheng Z, Zhou S, Chen Z, Zheng S, Lan E, Cui L, Ying H, Zhang Y, Lin X, Zhuang Q, Qian H, Hu X, Zhuang Y, Zhang Q, Jin Z, Jiang S, Ma Y.   +22 more
europepmc   +1 more source

Mechanistic insights into bone destruction in multiple myeloma: Cellular and molecular perspectives. [PDF]

J Bone Oncol
Lungu O, Toscani D, Giuliani N.
europepmc   +1 more source

TRIM44 facilitates aggressive behaviors in multiple myeloma through promoting ZEB1 deubiquitination. [PDF]

Discov Oncol
Qi H, Wang J, Cao L.
europepmc   +1 more source

Elevated LIF and JAK-STAT activation drive severe COVID-19 in myeloma patients receiving the BCMA-CD3 bispecific antibody Elranatamab. [PDF]

J Transl Med
Li Z, Zhang F, Jin X, Zhuang J.
europepmc   +1 more source

Abstracts

Molecular Oncology, Volume 19, Issue S1, Page 1-895, June 2025.
Abstracts submitted to the ‘EACR 2025 Congress: Innovative Cancer Science’, from 16–19 June 2025 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley   +1 more source

Calcium binding by a myeloma protein [PDF]

The American Journal of Medicine, 1979
We describe a patient with immunoglobulin G (IgG)-kappa myeloma and severe, long-standing, asymptomatic hypercalcemia. Serum nonprotein-bound calcium concentration was 5.2 mg/dl (normal 4.2 to 5.0 mg/dl) at a time when total serum calcium concentration was 17.8 mg/dl.
Deane F. Mosher, Jeffrey P. Jaffe
openaire   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Plasma cell myeloma with D-myeloma protein (IgD myeloma)

The American Journal of Medicine, 1968
Abstract Plasma cell myeloma distinguished by a serum D-myeloma protein has been found in many parts of the world and more than two dozen cases have been identified. Noteworthy observations are the high frequency (80 per cent) of D-myeloma protein with lambda-light chains (D-myeloma protein—type L) and the almost invariable presence of Bence Jones ...
Rolf Bachmann, Paul P. Carbone, David S. Rowe, John L. Fahey   +3 more
openaire   +3 more sources

Biological Properties of Myeloma Proteins

Archives of Internal Medicine, 1975
The paraproteins frequently cause major symptoms in patients with plasma cell dyscrasias. This may be due to their quantity in the circulation, to some unusual physicochemical property, or to a biological effect resulting in interaction with other serum proteins.
Espinoza Lr, Osterland Ck
openaire   +3 more sources